Tranexamic acid is not associated with decreased infection risk after primary shoulder arthroplasty: a cohort study of 9276 patients

J Shoulder Elbow Surg. 2023 Mar;32(3):581-588. doi: 10.1016/j.jse.2022.09.002. Epub 2022 Oct 5.

Abstract

Background: The use of tranexamic acid (TXA) is associated with less blood loss and reduced transfusion risk after shoulder arthroplasty surgery. Recent studies have shown lower odds of postoperative infection after hip or knee arthroplasty with its use. The purpose of this study was to determine whether TXA use reduces the risk of infection after primary elective shoulder arthroplasty.

Methods: A retrospective cohort study was conducted using data from a US integrated health care system's shoulder arthroplasty registry. Patients aged 18 years who underwent primary elective anatomic total shoulder arthroplasty for osteoarthritis or primary reverse shoulder arthroplasty for rotator cuff arthropathy were included (2013-2020). We compared patients who received preoperative intravenous TXA to those who did not receive TXA by assessing the risk for revision due to deep infection within 5 years' follow-up using multivariable Cox proportional hazard regression. Interaction between TXA and diabetes status was analyzed separately.

Results: The study sample included 9276 shoulder arthroplasties performed by 153 surgeons at 43 hospitals. The mean age was 70.0 years and 48% were male. The 5-year probability of revision for deep infection was 0.8% and 0.7% for patients with and without TXA, respectively. We failed to observe a difference in infection risk after adjustment for confounders and surgeon differences (hazard ratio [HR] 1.00, 95% confidence interval [CI] 0.56-1.80, P = .998). Further, no differences were observed in patients with (HR 1.64, 95% CI 0.42-6.44, P = .481) or without diabetes (HR 0.79, 95% CI 0.40-1.55, P = .488).

Conclusion: In a multicenter cohort of more than 9000 primary shoulder arthroplasty procedures, the use of preoperative TXA was not associated with a decrease in the 5-year probability of revision for deep infection.

Keywords: Shoulder arthroplasty; infection; registry; revision; tranexamic acid.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Antifibrinolytic Agents* / therapeutic use
  • Arthroplasty, Replacement, Shoulder* / adverse effects
  • Arthroplasty, Replacement, Shoulder* / methods
  • Blood Loss, Surgical
  • Cohort Studies
  • Female
  • Humans
  • Infections*
  • Male
  • Retrospective Studies
  • Tranexamic Acid* / therapeutic use

Substances

  • Tranexamic Acid
  • Antifibrinolytic Agents